NCT07187778 2026-01-05
Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal Cell Carcinoma (BLAZE)
M.D. Anderson Cancer Center
Phase 2 Recruiting
Clinical Trials
4 trialsNCT06677190 2025-11-05
Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin
Dana-Farber Cancer Institute
Phase 2 Recruiting
NCT07179770 2025-09-23
Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)
NYU Langone Health
Phase 1 Recruiting
NCT07167329 2025-09-11
BELIEVE-VHL
AC Camargo Cancer Center
Phase 2 Recruiting